O4 Hubs detail
O4 Detail Hero Banner

Drug Pipeline Insights Report

3 new first-in-class therapies coming

See how innovation is driving the latest product development.

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx­ | Published: April 2023

O4 1 Column (Full)
O4 Text Component

2023 will be a busy year for new pharmaceutical treatments.

O4 2 Columns (1/2 - 1/2)
O4 1 Column (Full)
O4 Text Component

Welcome to the next issue of Drugs to Watch for 2023

In this Drug Pipeline Insights Report, we review:

  • Two respiratory syncytial virus (RSV) vaccines
  • A gene therapy for Duchenne muscular dystrophy (DMD)
  • First FDA-approved treatment for nonalcoholic steatohepatitis (NASH), a rare liver disease

Download now

Don't want to read the full report? Download the brief summary.

View summary

Related Content

O4 Complex Card
O4 Complex Card

Which Rules Will Impact Pharmacy in 2023?

2023 is already a busy year for pharmacy regulation. Read about the latest regulations that could impact you and your pharmacy benefit plan.
O4 Complex Card

3 new drugs to watch this fall

As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.